RAPP EDWARD J 4

What Happened
Edward J. Rapp, a director of AbbVie Inc., was credited with 155 shares (stock-equivalent units) under a director fee award on March 31, 2026. The units are valued at $217.49 each, totaling about $33,711. This was an award/acquisition (derivative stock-equivalent units), a routine form of director compensation rather than an open-market purchase or sale.

Key Details

• Transaction date and price: 2026-03-31; 155 units @ $217.49 each.
• Total value: approximately $33,711.
• Transaction type: Award/Grant — derivative stock-equivalent units credited under a grantor trust.
• Shares/units owned after transaction: not specified in the filing.
• Filing date: 2026-04-02 (transaction dated 2026-03-31); filing not flagged as late.
• Footnotes: F1 — director fees credited to a stock-equivalent unit account under a grantor trust and paid in cash generally at age 65 or upon retirement; units track the return of AbbVie stock. F2 — balance includes units acquired via a dividend reinvestment feature.

Context
These are stock-equivalent units (derivatives), meaning the director did not necessarily receive tradable shares today but units that track AbbVie’s stock value and are typically paid in cash later per the trust terms. Such awards are standard compensation for board members and should be viewed as routine, not necessarily a direct signal of near-term insider sentiment.